CAS: 34184-77-5; (8S,13S,14S,17S)-13,17-Dimethyl-17-Propionyl-1,2,6,7,8,11,12,13,14,15,16,17-Dodecahydro-3H-Cyclopenta[a]Phenanthren-3-One

该化合物是一种合成类固醇和蛋白质,主要用于荷尔蒙疗法,其特点是能够与蛋白质受体结合,从而模仿人体中天然丙酮的影响,这种化合物经常用于各种医疗应用,包括避孕和治疗某些妇科疾病.普罗梅斯顿的抗色素特性可以有助于管理受雌激素水平影响的条件.其化学结构包括一种类固醇脊椎,典型的是蛋白质,允许它与激素受体有效互动.普罗梅斯顿的药理系系主要在肝脏中产生新陈代谢,导致各种代谢物的形成.与许多合成激素一样,必须监测潜在的副作用,其中可能包括情绪变化,体重波动和月经周期变化.

结构式图片

欧盟法规

ECHA物质C&L通报

上下游产品

黄体酮 Progesterone 57-83-0

合成工艺路线路线简述

    黄体酮,环戊丙酸雌二醇,1,4-Dithio-D,L-Threitol,Disodium;2-[2-[bis(Carboxymethyl)Amino]Ethyl-(Carboxylatomethyl)Amino]Acetate,三羟甲基氨基甲烷盐酸盐置于disodium;Dioxido(Dioxo)Molybdenum体系中,用 Sesame Oil,甘油 用作溶剂,化学反应 5.97H,以to Afford 20-40% Binding Of A Trace Of [3H]R5020 (90 Ci/mmol),10,000 Dpm,And 50 μl Of The Appropriate Radioinert Compound的收率获得普美孕酮
    参考文献:Progesterone Receptor Ligands
    标题:Progesterone Receptor Ligands
    摘要:制备了放射性和非放射性16.Alpha.-碘和17.Alpha.-(2-碘乙烯基)-19-去甲睾酮,并用于孕激素受体测定中.

    海关参考信息

    专利信息


    专利号:US-11897827-B1
    优先权日:2022-11-22
    标 题 :Carbon isotope exchange mediated by vanadium complexes
    发明人:BUKHRYAKOV KONSTANTIN
    权利人:BUKHRYAKOV KONSTANTIN; THE FLORIDA INTERNATIONAL UNIV BOARD OF TRUSTEES
    摘要:The subject invention provides catalytical compounds/complexes, compositions comprising such compound/complex, synthesis of the compounds/complexes, and methods of using such compounds/complexes as catalysts in, for example, carbon isotope exchange (CIE) on target bioactive molecules. Methods that allow CIE directly on drug candidates are of great importance to chemistry, biology, and medicine. Especially valuable are catalytic procedures that rely on a limited collection of available labeled materials. The instant method comprises converting a methyl group to terminal â•?CH2 utilizing transfer dehydrogenation catalysts to enable V-based olefin metathesis, followed by a hydrogenation step. The one-pot strategy allows the formal methylation/demethylation sequence and can be applied to an assortment of alkyl-containing compounds.

    专利号:US-2004162274-A1
    优先权日:2002-11-01
    标题 :Inhibition of steroid synthesis by use of progesterone or a progesterone receptor agonist
    发明人:PAUST HANS-JOACHIM; MUKHOPADHYAY AMAL K; PATCHEV VLADIMIR
    摘要:The present invention relates to the use of progesterone or a progesterone receptor agonist for the inhibition of steroid synthesis, in particular for inhibiting the expression of the steroidogenic acute regulatory protein (StAR protein).

    专利号:EP-1415653-A2
    优先权日:2002-11-01
    标 题:Use of progesterone or an agonist thereof for the inhibition of steroid synthesis

    专利号:DE-10251028-A1
    优先权日:2002-11-01
    标题 :Use of progesterone or a progesterone receptor agonist to inhibit steroid synthesis

    专利号:JP-2004155783-A
    优先权日:2002-11-01
    标题 :Inhibitor of steroid synthesis using progesterone or progesterone receptor agonist

    专利号:RU-2175969-C2
    优先权日:1995-11-06
    标题:Derivatives of 1-arylsulfonyl-, arylcarbonyl- or arylthiocar- bonylpyridazine, method of their synthesis, pharmaceutical composition
    台州百大药业有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.chinahormone.com
    电话: 0086-571-85215532/18167103925👤
    📞台州百大药业有限公司 ⚠️参考联系方式

    销售电话:0086-571-85215532/18167103925
    邮箱: taifa@chinahormone.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Uzan S, Denis C, Pomi V, Varin C. Double-blind trial of promegestone (R 5020) and lynestrenol in the treatment of benign breast disease. Eur J Obstet Gynecol Reprod Biol. 1992 Feb 28;43(3):219-27. French. doi: 10.1016/j.str.2014.04.013. Epub 2014 Jun 5.
    5: Speroni L, Whitt GS, Xylas J, Quinn KP, Jondeau-Cabaton A, Barnes C, Georgakoudi I, Sonnenschein C, Soto AM. Hormonal regulation of epithelial organization in a three-dimensional breast tissue culture model. Tissue Eng Part C Methods. 2014 Jan;20(1):42-51. doi: 10.1089/ten.TEC.2013.0054. Epub 2013 Jun 25.
    6: Tremollieres FA, Strong DD, Baylink DJ, Mohan S. Progesterone and promegestone stimulate human bone cell proliferation and insulin-like growth factor-2 production. Acta Endocrinol (Copenh). 1992 Apr;126(4):329-37. doi: 10.18632/oncotarget.5082.

    合成参考文献


    参考文献:10.1385/endo:16:3:217
    摘要:Pasapera AM, Gutiérrez-Sagal R, García-Becerra R, Ulloa-Aguirre A, Savouret JF. Transactivation of progestin- and estrogen-responsive promoters by 19-nor progestins in African Green Monkey Kidney CV1 cells. Endocrine. 2001 Dec;16(3):217–25. doi: 10.1385/endo:16:3:217.
    参考文献:10.1097/01.gme.0000097846.95550.aa
    摘要:Warming L, Ravn P, Spielman D, Delmas P, Christiansen C. Trimegestone in a low-dose, continuous-combined hormone therapy regimen prevents bone loss in osteopenic postmenopausal women. Menopause. 2004 May;11(3):337–42. doi: 10.1097/01.gme.0000097846.95550.aa.
    参考文献:10.2325/jbcs.13.129
    摘要:Sasano H, Suzuki T, Nakata T, Moriya T. New development in intracrinology of breast carcinoma. Breast Cancer. 2006;13(2):129–36. doi: 10.2325/jbcs.13.129.
    参考文献:10.1080/13697130801930385
    摘要:Pettersen PC, Raundahl J, Loog M, Nielsen M, Tankó LB, Christiansen C. Parallel assessment of the impact of different hormone replacement therapies on breast density by radiologist- and computer-based analyses of mammograms. Climacteric. 2008 Apr;11(2):135–43. doi: 10.1080/13697130801930385.
    参考文献:10.1371/journal.pone.0097311
    摘要:Vallejo G, La Greca AD, Tarifa-Reischle IC, Mestre-Citrinovitz AC, Ballaré C, Beato M, Saragüeta P. CDC2 Mediates Progestin Initiated Endometrial Stromal Cell Proliferation: A PR Signaling to Gene Expression Independently of Its Binding to Chromatin. PLoS ONE. 2014 May 23;9(5):e97311. doi: 10.1371/journal.pone.0097311.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知